Impact of PIVKA-II in diagnosis of hepatocellular carcinoma

Journal of Advanced Research

Volumn 4, Issue 6, 2013, Pages 539-546

  Zakhary, Nadia I ^a   Khodeer, Sherif M ^b   Shafik, Hanan E ^a   Abdel Malak, Camelia A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Mansoura University   (Egypt)

Author keywords

Early diagnosis; Hepatocelluler carcinoma; PIVKA II

Indexed keywords

EID: 84885861459     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2012.10.004     Document Type: Article

References (50)

1. Shibuya K., Yano E. Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972-2001. Int J Epidemiol 2005, 34:397-402.
2. Bosetti C., Levi F., Boffetta P., Lucchini F., Negri E., La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48:137-145.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
4. Mazzanti R., Gramantieri L., Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 2008, 29:130-143.
5. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
6. Mokhtar NM., Gouda I., Adel I. Cancer pathology registry (2003-2004) and time trend analysis 2007, NCI, Cairo University. N.M. Mokhtar, I. Gouda, I. Adel (Eds.).
7. Yu M.C., Yuan J.M., Lu S.C. Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23(Suppl 1):S92-97.
8. Alacacioglu A., Somali I., Simsek I., Astarcioglu I., Ozkan M., Camci C., et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol 2008, 38:683-688.
9. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G., Romeo R., et al. Colombo, Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
10. Habib M., Mohamed M.K., Abdel-Aziz F., Magder L.S., Abdel-Hamid M., Gami Fl, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001, 33:248-253.
11. Kamal S.M., Madwar M.A., Peters T., Fawzy R., Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172-174.
12. El-Nady G.M., Ling R., Harrison T.J. Gene expression in HCV-associated hepatocellular carcinoma-upregulation of a gene encoding a protein related to the ubiquitin-conjugating enzyme. Liver Int 2003, 23:329-337.
13. Bosch F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285.
14. Szabo E., Paska C., Kaposi Novak P., Schaff Z., Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004, 10:5-11.
15. Yao D.F., Dong Z.Z., Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007, 6:241-247.
16. Daniele B., Bencivenga A., Megna A.S., Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127(Suppl):S108-S112.
17. Bertino G., Ardiri A., Malaguarnera M., Malaguarnera G., Bertino N., Calvagno G.S. Hepatocellualar carcinoma serum markers. Semin Oncol 2012, 39(4):410-433.
18. Nguyen M.H., Garcia R.T., Simpson P.W., Wright T.L., Keeffe E.B. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002, 36:410-417.
19. Sheu J.C., Sung J.L., Chen D.S., Lai M.Y., Wang T.H., Yu J.Y., et al. Early detection of hepatocellular carcinoma by real-time ultrasonography, a prospective study. Cancer 1985, 56:660-666.
20. Ono M., Ohta H., Ohhira M., Sekiya C., Namiki M. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol 1990, 11:319-326.
21. Fujioka M., Nakashima Y., Nakashima O., Kojiro M. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001, 34:1128-1134.
22. Cui R., Wang B., Ding H., Shen H., Li Y., Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J (Engl) 2002, 115:42-45.
23. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37:1114-1121.
24. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M. Serum markers of hepatocelluler carcinoma. Dig Dis Sci 2010, 55(10):2744-2755.
25. Bertino G., Neri S., Bruno C.M., Ardiri A.M., Calvagno G.S., Malaguarnera M., et al. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 2011, 102(5):363-371.
26. Thomas L. Clinical laboratory diagnostics 1998, TH Books Verlagsgesellschaft, Frankfurt, p. 644-7. 1st ed.
27. Lovet J.M., Bru C., Bruix J. Prognosis of HCC: the BCLC staging classification. Seminars in Liver Dis 1999, 19:329-338.
28. Pugh R.N., Murray-Lyon I.M., Dawson J.L. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 646-649.
29. Zaman S.N., Melia W.M., Johnson R.D., Portmann B.C., Johnson P.J., Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985, 1:1357-1360.
30. Kawano Y., Sasaki A., Kai S., Endo Y., Iwaki K., Uchida H., et al. Short and long term outcomes after hepatic resection for hepatocellular carcinoma with concomitant esophageal varices in patients with cirrhosis. Ann Surg Oncol 2008, 15:1670-1676.
31. Stefaniuk P., Cianciara J., Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010, 16:418-424.
32. Libbrecht L., Severi T., Cassiman D., Vander Borght S., Pirenne J., Nevens F., et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30:1405-1411.
33. Zinkin N.T., Grall F., Bhaskar K., Otu H.H., Spentzos D., Kalmowitz B., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008, 14:470-477.
34. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
35. Poon D., Anderson B.O., Chen L.T., Tanaka K., Lau W.Y., Van Cutsem E., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
36. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
37. Parkin D.M., Muir C.S., Whelan S.L. Cancer incidence in five continents 1997, vol. 5. International Agency for Research on Cancer, IARC Lyon.
38. Okuda K. Epidemiology of primary liver cancer. Primary liver cancer in Japan 2003, 3. Springer-Verlag, Tokyo. T. Tobe (Ed.).
39. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Takasaki K., et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000, 88:544-549.
40. Gotoh M., Nakatani T., Masuda T., Mizuguchi Y., Sakamoto M., Tsuchiya R., et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol 2003, 33:522-526.
41. El-Assaly N.M., El Ashry I.N., Mostafa I., El Ghannam M., Attia M. Serum chromogranin-A and serum PIVKA-II as useful complementary and diagnostic markers for HCC. Res J Med Med Sci 2008, 4(2):391-401.
42. Durazo F.A., Blatt L.M., Corey W.G., Lin J.H., Han S., Saab S., et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:1541-1548.
43. Nagaoka S., Yatsuhashi H., Hamada H., Yano K., Matsumoto T., Daikoku M., et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003, 98:2671-2677.
44. Kaibori M., Matsui Y., Yanagida H., Yokoigawa N., Kwon A.H., Kamiyama Y. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg 2004, 28:702-707.
45. Baek Y.H., Lee J.H., Jang J.S., Lee S.W., Han J.Y., Jeong J.S., et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009, 56:763-767.
46. Bae H.M., Lee J.H., Yoon J.H., Kim Y.J., Heo D.S., Lee H.S. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer 2011, 10:11-435.
47. Mita Y., Aoyagi Y., Yanagi M., Suda T., Suzuki Y., Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998, 82:1643-1648.
48. Cui R., He J., Zhang F., Wang B., Ding H., Shen H., et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003, 88:1878-1882.
49. Gao P., Li M., Tian Q.B., Liu D.W. Diagnostic performance of des-γ-carboxy prothrombin (DCP) for hepatocellular carcinoma: a bivariate meta-analysis. Neoplasma 2012, 59(2):150-159.
50. Bertino G., Ardiri A.M., Calvagno G.S., Bertino N., Boemi P.M. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect 2010, 23(8):498-508.